Evaxion announced that their personalized cancer vaccine EVX-01 maintained clinical responses in all advanced melanoma patients at a three-year follow-up in a phase 2 trial, with no tumor progression observed. Initially combined with Merck's KEYTRUDA, EVX-01 was given as stand-alone therapy in the third year, showing durable benefits including a 75% objective response rate and 25% complete response rate at two years. These results highlight the vaccine's potential as a novel immunotherapy and will be presented at the ESMO 2026 Congress, supporting further development and partnership opportunities.
Evaxion's personalized cancer vaccine EVX-01 clinical results provide context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 13:11 WIB: out of 150 priced US health-sector stocks, 79 rose and 65 fell. Notable movers include IDXX at USD 560.36 with a 1-day change of +5.93%, COO at USD 57.94 with +5.58%, and ACHC at USD 29.98 with -5.34%.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
